Prosecution Insights
Last updated: April 19, 2026

Examiner: FOLEY, SHANON A

Tech Center 1600 • Art Units: 1619 1648 1671

This examiner grants 74% of resolved cases

Performance Statistics

73.8%
Allow Rate
+13.8% vs TC avg
997
Total Applications
+18.0%
Interview Lift
1039
Avg Prosecution Days
Based on 958 resolved cases, 2023–2026

Rejection Statute Breakdown

6.1%
§101 Eligibility
20.6%
§102 Novelty
30.2%
§103 Obviousness
26.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17779484 MODIFIED VIRAL THERAPEUTICS AND USES THEREOF Final Rejection THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
19295239 THERMOSTABLE MUCOSAL VACCINE COMPOSITIONS AND METHODS Final Rejection GLOBAL HEALTH SOLUTIONS, INC.
18024542 IMMUNOGENIC COMPOSITIONS AND USES THEREOF Final Rejection Flagship Pioneering Innovations VI, LLC
19073006 mRNA vaccine for porcine Deltacoronavirus, preparation method and application thereof Final Rejection Jiangsu Academy of Agricultural Sciences
19016420 VACCINES COMPRISING PROTEINS AND/OR PEPTIDES OF METHANOBREVIBACTER GOTTSCHALKII Non-Final OA Arkea Bio Corp.
17272199 COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING VIRUS INFECTION Final Rejection University of Virginia Patent Foundation
18279314 METHODS AND COMPOSITIONS FOR DETECTING AND PRODUCING PORCINE MORBILLIVIRUS AND VACCINES THEREOF Non-Final OA Iowa State University Research Foundation, Inc.
18557987 VACCINATION AGAINST BACTERIAL AND BETACORONAVIRUS INFECTIONS Non-Final OA PFIZER INC.
17312185 Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof Non-Final OA Pfizer Inc.
18048776 COMPOSITIONS AND METHODS FOR TREATING ANAL HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL) Final Rejection Inovio Pharmaceuticals, Inc.
17771736 IMPROVED VACCINES FOR RECURRENT RESPIRATORY PAPILLOMATOSIS AND METHODS FOR USING THE SAME Non-Final OA Inovio Pharmaceuticals, Inc.
18064482 LARGE AND SMALL T ANTIGENS OF MERKEL CELL POLYOMAVIRUS, NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM, AND METHODS OF USING SAME Non-Final OA THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
18003056 COMBINATION PORCINE VACCINE Final Rejection BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
18501677 RECOMBINANT RSV VACCINE: METHODS OF MAKING AND USING THE SAME Non-Final OA BLUE LAKE BIOTECHNOLOGY, INC.
18283130 METHOD OF ELICITING AN IMMUNE RESPONSE AGAINST RESPIRATORY SYNCYTIAL VIRUS Non-Final OA CODAGENIX INC.
18546427 GENETICALLY MODIFIED CLOSTRIDIUM STRAINS EXPRESSING RECOMBINANT ANTIGENS AND USES THEREOF Non-Final OA LIVINGMED BIOTECH S.R.L.
18254154 C-TERMINUS MODIFIED HUMAN PAPILLOMAVIRUS TYPE 6 L1 PROTEIN AND USE THEREOF Non-Final OA INSTITUTE OF BASIC MEDICAL SCIENCES, CHINESE ACADEMY OF MEDICAL SCIENCES
18245233 COMPOSITIONS AND METHODS TARGETING FILAMENTOUS BACTERIOPHAGE Final Rejection INIMMUNE CORPORATION
18043631 TREATMENT AND PREVENTION OF VIRAL INFECTIONS Non-Final OA Sporegen Limited
18021972 CORONAVIRUS VACCINE AND METHOD FOR PREPARATION THEREOF Non-Final OA BHARAT BIOTECH INTERNATIONAL LIMITED
18041883 SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS [SARS-CoV-2]-VIRUS-LIKE PARTICLE [VLP] VACCINE: COMPOSITIONS, DELIVERY STRATEGIES, METHODS AND USES Non-Final OA TECHNOVAX, INC.
18007036 MODIFIED CHIKUNGUNYA VIRUSES AND SINDBIS VIRUSES AND USES THEREOF Non-Final OA Replicate Bioscience, Inc.
18016137 LIVE-ATTENUATED VIRUS VACCINE Non-Final OA INDIAN IMMUNOLOGICALS LIMITED
18005367 Subunit Vaccine Composition For African Swine Fever, And Preparation Therefor And Use Thereof Final Rejection NOVO BIOTECH CORP
18003799 RECOMBINANT ENTEROVIRUSES AND USES THEREOF Non-Final OA Aleph Therapeutics, Inc.
17735019 PARTICLES FOR STIMULATING AN IMMUNE RESPONSE AGAINST VIRAL INFECTIONS Final Rejection FINNCURE OY
17631845 A METHOD OF ELICITING AN IMMUNE RESPONSE BY ADMINISTERING A POPULATION OF POLYMERSOMES HAVING AN ASSOCIATED ANTIGEN TOGETHER WITH A POPULATION OF POLYMERSOMES HAVING AN ASSOCIATED ADJUVANT AS WELL AS COMPOSITIONS COMPRISING THE TWO POPULATIONS OF POLYMERSOMES Final Rejection ACM BIOLABS PTE LTD
17539667 PSORALEN-INACTIVATED CORONAVIRUS VACCINE AND METHOD OF PREPARATION Non-Final OA The United States of American as Represented by the Secretary of the Navy
17324756 Manufacture of Virus Non-Final OA KaliVir Immunotherapeutics, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month